IL250391B - Crystalline forms of glutaminase inhibitors - Google Patents

Crystalline forms of glutaminase inhibitors

Info

Publication number
IL250391B
IL250391B IL250391A IL25039117A IL250391B IL 250391 B IL250391 B IL 250391B IL 250391 A IL250391 A IL 250391A IL 25039117 A IL25039117 A IL 25039117A IL 250391 B IL250391 B IL 250391B
Authority
IL
Israel
Prior art keywords
crystal forms
glutaminase inhibitors
glutaminase
inhibitors
crystal
Prior art date
Application number
IL250391A
Other languages
English (en)
Hebrew (he)
Other versions
IL250391A0 (en
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of IL250391A0 publication Critical patent/IL250391A0/en
Publication of IL250391B publication Critical patent/IL250391B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL250391A 2014-08-07 2017-02-01 Crystalline forms of glutaminase inhibitors IL250391B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034547P 2014-08-07 2014-08-07
PCT/US2015/044301 WO2016022969A1 (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Publications (2)

Publication Number Publication Date
IL250391A0 IL250391A0 (en) 2017-03-30
IL250391B true IL250391B (en) 2021-10-31

Family

ID=55264662

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250391A IL250391B (en) 2014-08-07 2017-02-01 Crystalline forms of glutaminase inhibitors

Country Status (13)

Country Link
US (2) US10316030B2 (enExample)
EP (1) EP3193876B1 (enExample)
JP (3) JP6889101B2 (enExample)
KR (1) KR20170082494A (enExample)
CN (1) CN106999490A (enExample)
AU (2) AU2015300825B2 (enExample)
BR (1) BR112017002403A2 (enExample)
CA (1) CA2957225A1 (enExample)
EA (1) EA037738B1 (enExample)
IL (1) IL250391B (enExample)
MX (1) MX2017001620A (enExample)
SG (1) SG11201700816YA (enExample)
WO (1) WO2016022969A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2420498T (lt) 2006-09-26 2017-10-25 Celgene Corporation 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
EA026100B1 (ru) 2011-03-11 2017-03-31 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EP3277276B1 (en) * 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2019089854A1 (en) * 2017-10-31 2019-05-09 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
JP2022528355A (ja) * 2019-03-26 2022-06-10 トニックス ファーマ ホールディングス リミテッド Ｓ－（ｎ，ｎ－ジエチルカルバモイル）グルタチオンの塩形態
CN114295836B (zh) * 2021-12-22 2024-12-31 融智生物科技（青岛）有限公司 一种计算设备、存储介质和胶质瘤idh分型检测装置及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078645A1 (en) * 2012-11-16 2014-05-22 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
RU2009114159A (ru) 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
EP2396313A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of thalidomide
PL2536706T3 (pl) 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
JP5712882B2 (ja) * 2011-09-28 2015-05-07 株式会社豊田自動織機 電動圧縮機用の電動モータ
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HUE047642T2 (hu) 2011-11-21 2020-05-28 Calithera Biosciences Inc A glutamináz heterociklusos gátlói
WO2013177426A2 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
CA2884103A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
ES2690829T3 (es) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EP3277276B1 (en) 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
KR20190125432A (ko) 2017-03-10 2019-11-06 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078645A1 (en) * 2012-11-16 2014-05-22 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAYNES, DELIA A., WILLIAM JONES, AND WD SAMUEL MOTHERWELL., OCCURRENCE OF PHARMACEUTICALLY ACCEPTABLE ANIONS AND CATIONS IN THE CAMBRIDGE STRUCTURAL DATABASE., 31 October 2005 (2005-10-31) *

Also Published As

Publication number Publication date
EA201790337A1 (ru) 2017-09-29
MX2017001620A (es) 2017-05-10
JP2017523991A (ja) 2017-08-24
EP3193876A4 (en) 2017-12-27
CN106999490A (zh) 2017-08-01
AU2015300825A1 (en) 2017-03-09
IL250391A0 (en) 2017-03-30
EP3193876A1 (en) 2017-07-26
EP3193876B1 (en) 2022-01-12
SG11201700816YA (en) 2017-02-27
AU2015300825B2 (en) 2019-10-10
KR20170082494A (ko) 2017-07-14
US20190359607A1 (en) 2019-11-28
AU2019284149A1 (en) 2020-01-30
US10676472B2 (en) 2020-06-09
WO2016022969A1 (en) 2016-02-11
BR112017002403A2 (pt) 2017-12-05
EA037738B1 (ru) 2021-05-17
JP6889101B2 (ja) 2021-06-18
JP2021165286A (ja) 2021-10-14
US20170226101A1 (en) 2017-08-10
US10316030B2 (en) 2019-06-11
CA2957225A1 (en) 2016-02-11
JP2020037588A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
ZA201604272B (en) Inhibitors of glutaminase
IL250391A0 (en) Crystalline forms of glutaminase inhibitors
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
ZA201801417B (en) Salts of an lsd1 inhibitor
IL249476A0 (en) Combined treatment with glutaminase inhibitors
IL250046B (en) Spirocycloheptanes as rock inhibitors
SG11201708034SA (en) Methods of administering glutaminase inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL273463A (en) Crystalline forms of immunomodulators
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL253018A0 (en) Crystalline forms of apomorphine and their uses
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
EP3164195A4 (en) Glutaminase inhibitor therapy
HK1228907A1 (en) Novel inhibitors of glutaminase
HK1228906A1 (en) Novel glutaminase inhibitors
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors